An official website of the United States government
NIH Guide: Weekly Index for January 10, 2020
Weekly NIH Funding Opportunities and Notices
January 10, 2020
Policy Notices
-
AHRQ Guide Notice on Implementation of the Use of a Single Institutional Review Board (IRB) for Cooperative Research at 45 CFR 46.114 (b)
(NOT-HS-20-005)Agency for Healthcare Research and Quality
General Notices
-
Notice of Technical Assistance Webinar for NHLBI RFA-HL-21-011 "Stimulating T4 Implementation Research to Optimize Integration of Proven-effective Interventions for Heart, Lung, and Blood Diseases and Sleep Disorders into Practice (STIMULATE-2) (R61/R33)"
(NOT-HL-20-748)National Heart, Lung, and Blood Institute
Notice of Changes to Funding Opportunities
-
Notice of NIAAA Participation in PA-18-935 "Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)"
(NOT-AA-19-034)National Institute on Alcohol Abuse and Alcoholism
-
Notice of NIDA Participation in PAR-19-343, "Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 - Independent Clinical Trial Not Allowed)"
(NOT-DA-20-029)National Institute on Drug Abuse
-
Notice of NIDCR Participation in PAR-19-373 "Research on biopsychosocial factors of social connectedness and isolation on health, wellbeing, illness, and recovery (R01 Clinical Trials Not Allowed)"
(NOT-DE-20-004)National Institute of Dental and Craniofacial Research
-
Notice of NIDCR Participation in PAR-19-384 "Research on biopsychosocial factors of social connectedness and isolation on health, wellbeing, illness, and recovery (R01 Basic Experimental Studies with Humans Required)"
(NOT-DE-20-005)National Institute of Dental and Craniofacial Research
-
Notice of Change: Emphasizing an Opportunity for New Institutional Applicants in Response to PAR-19-204 Centers of Excellence in Genomic Science (RM1 Clinical Trial Optional)
________________________________________
(NOT-HG-20-013)National Human Genome Research Institute
-
Notice of Change in Expiration Date of PAR-17-338 "Continuation of Existing Grant Based Epidemiology Cohort Studies in Heart, Lung, Blood, and Sleep Diseases andDisorders (U01-Clinical Trials Not Allowed)"
(NOT-HL-19-474)National Heart, Lung, and Blood Institute
-
Addition of SBIR Direct-to-Phase II Program to NINDS RFA-NS-18-012, "Translational Neural Devices (U44 Clinical Trial Required)"
(NOT-NS-20-034)National Institute of Neurological Disorders and Stroke
Notices of Intent to Publish
-
Notice of Intent to Publish a Funding Opportunity Announcement for Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)
(NOT-NS-20-032)National Institute of Neurological Disorders and Stroke
-
Notice of Intent to Publish a Funding Opportunity Announcement for Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
(NOT-NS-20-033)National Institute of Neurological Disorders and Stroke
Notices of Special Interest
-
HEAL Initiative: Back Pain Consortium (BACPAC) Research Program Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions.
(NOT-AR-20-012)National Institute of Arthritis and Musculoskeletal and Skin DiseasesNational Institute on Alcohol Abuse and AlcoholismNational Institute on Drug AbuseEunice Kennedy Shriver National Institute of Child Health and Human DevelopmentNational Institute of Nursing ResearchNational Institute of Neurological Disorders and StrokeNational Center for Advancing Translational SciencesNational Center for Complementary and Integrative HealthNational Institute of Biomedical Imaging and BioengineeringOffice of Research on Women's HealthOffice of Behavioral and Social Sciences ResearchNational Institute on Minority Health and Health DisparitiesNational Center for Advancing Translational Sciences
-
Notice of Special Interest (NOSI): De-implementation of Ineffective or Low-value Clinical Practices along the Cancer Care Continuum
(NOT-CA-20-021)National Cancer Institute
-
Notice of Special Interest (NOSI): Preclinical and Clinical Studies of the Interactions of Opioids and Stimulants
(NOT-DA-20-007)National Institute on Drug Abuse
-
Notice of Special Interest (NOSI): Biomarkers and Biotypes of Drug Addiction
(NOT-DA-20-012)National Institute on Drug Abuse
-
Notice of Special Interest: Administrative Supplements for Existing NIH Countermeasures Against Chemical Threats (CounterACT) Program Research Grants and Cooperative Agreement Awards
(NOT-NS-20-029)National Institute of Neurological Disorders and StrokeNational Institute of Arthritis and Musculoskeletal and Skin DiseasesNational Institute on Drug AbuseNational Institute of Environmental Health SciencesNational Eye Institute
-
Notice of Special Interest: Administrative Supplements to Promote and Expand into the Research and Development of Medical Countermeasures Against Chemical Threats
(NOT-NS-20-030)National Institute of Neurological Disorders and StrokeNational Institute of Arthritis and Musculoskeletal and Skin DiseasesNational Institute on Drug AbuseNational Institute of Environmental Health SciencesNational Eye Institute
-
Notice of Special Interest: Countermeasures Against Chemical Threats (CounterACT) U54 Centers of Excellence will only support targeted chemical threats of interest
(NOT-NS-20-031)National Institute of Neurological Disorders and StrokeNational Institute of Arthritis and Musculoskeletal and Skin DiseasesNational Institute on Drug AbuseNational Institute of Environmental Health SciencesNational Eye Institute
Funding Opportunities
-
Development of Highly Innovative Tools and Technology for Analysis of Single Cells (STTR) (R41/R42 Clinical Trial Not Allowed)
(PA-20-025)National Institute of Mental HealthNational Institute of General Medical SciencesNational Institute on Drug AbuseNational Institute of Dental and Craniofacial ResearchNational Institute of Environmental Health SciencesNational Eye InstituteNational Human Genome Research InstituteNational Center for Advancing Translational SciencesNational Center for Advancing Translational SciencesApplication Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization.
-
Development of Highly Innovative Tools and Technology for Analysis of Single Cells (SBIR) (R43/R44 Clinical Trial Not Allowed)
(PA-20-047)National Institute of Mental HealthNational Institute of General Medical SciencesNational Cancer InstituteNational Institute on Drug AbuseNational Institute of Dental and Craniofacial ResearchNational Institute of Environmental Health SciencesNational Eye InstituteNational Human Genome Research InstituteNational Center for Advancing Translational SciencesNational Center for Advancing Translational SciencesApplication Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization.
-
Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Not Allowed)
(PAR-20-037)National Institute of Mental HealthNational Institute on Alcohol Abuse and AlcoholismNational Institute on AgingApplication Receipt Date(s): Standard dates apply. The first standard application due date for this FOA is February 5, 2020
-
Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01 Clinical Trial Optional)
(PAR-20-038)National Institute of Mental HealthNational Institute on Alcohol Abuse and AlcoholismNational Institute on AgingApplication Receipt Date(s): Standard dates apply The first standard application due date for this FOA is February 5, 2020.
-
Enhancing Regulatory Science for Advancing Pharmaceutical Quality and Manufacturing (U01) Clinical Trials Optional
(PAR-20-083)Food and Drug AdministrationApplication Receipt Date(s): April 10, 2020, by 11:59 PM Eastern Time. April 5, 2021, by 11:59 PM Eastern Time. April 4, 2022, by 11:59 PM Eastern Time.
-
NIBIB Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)
(PAR-20-084)National Institute of Biomedical Imaging and BioengineeringNational Institute on AgingApplication Receipt Date(s): Standard dates apply.
-
Pilot Centers for Precision Disease Modeling (U54)(Clinical Trials Not Allowed)
(PAR-20-085)Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure ProgramsApplication Receipt Date(s): June 24, 2020
-
Infrastructure for the Expansion of Rhesus macaque Colonies to Support HIV/AIDS-related Research (C06 Clinical Trial Not Allowed)
(PAR-20-087)Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure ProgramsApplication Receipt Date(s): March 6, 2020. All applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Digital, Limited Interaction Trials and Epidemiology (D-LITE): Targeting HIV Incidence in the United States (U01 Clinical Trial Required)
(RFA-AI-19-067)National Institute of Allergy and Infectious DiseasesEunice Kennedy Shriver National Institute of Child Health and Human DevelopmentNational Institute of Mental HealthApplication Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below.
-
Radiobiology of High Linear Energy Transfer (High LET) Exposure in Cancer Treatment (R01, Clinical Trial Not Allowed)
(RFA-CA-20-032)National Cancer InstituteApplication Receipt Date(s): March 19, 2020
-
Center for Collaborative Research on Complex Generics (U18) Clinical Trials Optional
(RFA-FD-20-007)Food and Drug AdministrationApplication Receipt Date(s): April 13, 2020
-
Renewal - Investigation of impact of manufacturing difference and formulation variation on drug release for Levonorgestrel Intrauterine System (U01) Clinical Trials Not Allowed
(RFA-FD-20-020)Food and Drug AdministrationApplication Receipt Date(s): New Date March 31, 2020, by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date. Late applications will not be accepted for this FOA.
-
Animal and Biological Material Resource Centers (P40) (Clinical Trials Not-Allowed)
(RFA-OD-20-002)Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure ProgramsApplication Receipt Date(s): January 7, 2023
-
MoTrPAc Phase 2 Animal Studies (U01 Clinical Trial Not Allowed)
(RFA-RM-20-009)Office of Strategic Coordination (Common Fund)Application Receipt Date(s): March 20, 2020
NIH Funding Opportunities are also available in an RSS feed (Really Simple Syndication).
Subscribe/Unsubscribe from the NIH Guide Weekly TOC LISTSERV.
For technical issues E-mail OER Webmaster